Skip to content
10-K

Annual Report

CUMBERLAND PHARMACEUTICALS INC CPIX

0001628280-25-011366

← back to feed
Filed
Mar 7, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 4, 2025 13.97M sh
Eps Diluted FY 2024 · Dec 31, 2024 −$0.14
Eps Diluted FY 2024 · Sep 30, 2024 −$0.11
Eps Diluted FY 2024 · Jun 30, 2024 −$0.08
Eps Diluted FY 2024 · Mar 31, 2024 −$0.14
Eps Diluted FY 2024 · Dec 31, 2023 −$0.44
Eps Basic FY 2024 · Dec 31, 2024 −$0.14
Eps Basic FY 2024 · Sep 30, 2024 −$0.11
Eps Basic FY 2024 · Jun 30, 2024 −$0.08
Eps Basic FY 2024 · Mar 31, 2024 −$0.14
Eps Basic FY 2024 · Dec 31, 2023 −$0.44
Shares Diluted FY 2024 · Dec 31, 2023 14.3M sh
Stock Repurchased FY 2024 · Dec 31, 2023 $740.53K
Capex FY 2024 · Dec 31, 2023 $281.27K
Operating Cash Flow FY 2024 · Dec 31, 2023 $6.09M
Short Term Debt FY 2024 · Dec 31, 2023 $0
Cash And Equivalents FY 2024 · Dec 31, 2023 $18.32M
Stockholders Equity FY 2024 · Dec 31, 2023 $29.6M
Current Liabilities FY 2024 · Dec 31, 2023 $27.98M
Total Liabilities FY 2024 · Dec 31, 2023 $52.52M
Current Assets FY 2024 · Dec 31, 2023 $35.71M
Total Assets FY 2024 · Dec 31, 2023 $81.78M
Sga Expense FY 2024 · Dec 31, 2023 $10.65M
Rd Expense FY 2024 · Dec 31, 2023 $5.83M
Net Income FY 2024 · Dec 31, 2023 −$6.29M
Net Income FY 2024 · Dec 31, 2023 −$6.28M
Net Income FY 2024 · Sep 30, 2023 −$1.05M
Net Income FY 2024 · Jun 30, 2023 $872.2K
Net Income FY 2024 · Mar 31, 2023 $192.18K
Operating Income FY 2024 · Dec 31, 2023 −$6.18M
Operating Income FY 2024 · Dec 31, 2023 −$9.55M
Operating Income FY 2024 · Sep 30, 2023 −$1.87M
Operating Income FY 2024 · Jun 30, 2023 $22.86K
Operating Income FY 2024 · Mar 31, 2023 −$1.53M
Cost Of Revenue FY 2024 · Dec 31, 2023 $6.07M
Revenue FY 2024 · Dec 31, 2023 $9.35M
Revenue FY 2024 · Dec 31, 2023 $39.55M
Revenue FY 2024 · Sep 30, 2023 $10.09M
Revenue FY 2024 · Jun 30, 2023 $10.89M
Revenue FY 2024 · Mar 31, 2023 $9.22M